Research a compound stack end to end — a structured protocol scaffold, how VialTalk researchers actually combine these compounds, receptor conflicts, and live COA-verified prices. Add 1–5 compounds.
Research signals
Redundancy, true conflicts, and dangerous additive effects
Review advised
No documented conflicts — some notes to review
Receptor activity map
| Receptor | Dual Incret… | MOTS-c | NAD+ | GHK-Cu |
|---|---|---|---|---|
| GLP-1R (Glucagon-like peptide-1 receptor) | ||||
| GIPR (Glucose-dependent insulinotropic polypeptide receptor) | ||||
| AMPK pathway | ||||
| Sirtuin/PARP/CD38 (NAD+ consumer axis) | ||||
| SIRT1 expression/STAT3 pathway | ||||
| Copper-dependent enzyme/connective-tissue remodeling axis | ||||
| GLUT4 translocation/mitofusion axis |
A structured, research-grounded protocol for this stack
Sign in to build a structured research protocol scaffold for GHK-Cu + NAD+ + MOTS-c + Dual Incretin Agonist — phases, per-compound parameters, endpoints and washout, grounded in documented research.
What VialTalk researchers actually run
No researchers have logged this exact combination yet — yours could be the first.
Researchers are also adding
Best price for each compound today
Same “From” price shown on each compound's page (after discounts). Panels = COA assays tested. Tap “Compare all vendors” for the full breakdown.
For research and informational use only. VialTalk does not provide medical advice or dosing guidance. Community data reflects self-reported public research journals.